LU92213I2 - Insuline dégludec sous toutes les formes protégéespar le brevet de base - Google Patents
Insuline dégludec sous toutes les formes protégéespar le brevet de baseInfo
- Publication number
- LU92213I2 LU92213I2 LU92213C LU92213C LU92213I2 LU 92213 I2 LU92213 I2 LU 92213I2 LU 92213 C LU92213 C LU 92213C LU 92213 C LU92213 C LU 92213C LU 92213 I2 LU92213 I2 LU 92213I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- insulin degludec
- basic patent
- forms protected
- protected
- forms
- Prior art date
Links
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 title 1
- 108010050259 insulin degludec Proteins 0.000 title 1
- 229960004225 insulin degludec Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301129 | 2003-08-05 | ||
| US49545103P | 2003-08-14 | 2003-08-14 | |
| EP04739008A EP1660531A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LU92213I2 true LU92213I2 (fr) | 2013-08-23 |
| LU92213I9 LU92213I9 (enExample) | 2018-11-19 |
Family
ID=34117520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92213C LU92213I2 (fr) | 2003-08-05 | 2013-06-10 | Insuline dégludec sous toutes les formes protégéespar le brevet de base |
| LU92226C LU92226I2 (fr) | 2003-08-05 | 2013-06-19 | Combination d'insuline dégludec et insuline asparte sous toutes les formes protégées par le brevet de base |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92226C LU92226I2 (fr) | 2003-08-05 | 2013-06-19 | Combination d'insuline dégludec et insuline asparte sous toutes les formes protégées par le brevet de base |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7615532B2 (enExample) |
| EP (3) | EP2107069B1 (enExample) |
| JP (1) | JP4463814B2 (enExample) |
| KR (1) | KR101159559B1 (enExample) |
| AU (2) | AU2004261353B2 (enExample) |
| BE (2) | BE2013C035I2 (enExample) |
| BR (1) | BRPI0413276B8 (enExample) |
| CA (1) | CA2531988C (enExample) |
| CY (5) | CY1113850T1 (enExample) |
| FR (2) | FR13C0035I2 (enExample) |
| HU (1) | HUS1300033I1 (enExample) |
| IL (1) | IL172980A (enExample) |
| LU (2) | LU92213I2 (enExample) |
| MX (1) | MXPA06001283A (enExample) |
| NO (5) | NO340925B1 (enExample) |
| PL (1) | PL2107069T3 (enExample) |
| RU (1) | RU2518460C2 (enExample) |
| WO (1) | WO2005012347A2 (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA008433B1 (ru) * | 2003-07-25 | 2007-06-29 | Конджачем Биотекнолоджис Инк. | Производные инсулина длительного действия и способы их использования |
| CA2531988C (en) | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| ES2438145T3 (es) * | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | Nuevos derivados de insulina |
| ES2490243T3 (es) * | 2005-02-02 | 2014-09-03 | Novo Nordisk A/S | Derivados de insulina |
| JP4808785B2 (ja) * | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー／エス | インスリン組成物および組成物の製造方法 |
| JP5202338B2 (ja) * | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | 新規インシュリン誘導体 |
| WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| WO2007127236A2 (en) | 2006-04-28 | 2007-11-08 | Acrymed, Inc. | Antimicrobial site dressings |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| EP2024390B1 (en) * | 2006-05-09 | 2015-08-19 | Novo Nordisk A/S | Insulin derivative |
| AU2007247109B2 (en) * | 2006-05-09 | 2012-03-15 | Novo Nordisk A/S | Insulin derivative |
| JP5097900B2 (ja) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | 有機酸又はこれらの誘導体の活性エステル体の製造方法 |
| JP5550338B2 (ja) * | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | ペグ化持続型インスリン |
| US9018161B2 (en) | 2006-09-22 | 2015-04-28 | Novo Nordisk A/S | Protease resistant insulin analogues |
| US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| AU2008257505B2 (en) * | 2007-06-01 | 2013-05-16 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
| ES2744384T3 (es) * | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| AU2008288413B2 (en) * | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| US8962794B2 (en) | 2007-08-15 | 2015-02-24 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
| JP5715418B2 (ja) * | 2007-11-08 | 2015-05-07 | ノボ・ノルデイスク・エー／エス | インスリン誘導体 |
| ES2430042T3 (es) | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| ES2618073T3 (es) | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| WO2010029159A1 (en) | 2008-09-12 | 2010-03-18 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| EP2352513B1 (en) * | 2008-10-30 | 2016-09-14 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| MX2011007544A (es) | 2009-01-23 | 2011-08-12 | Novo Nordisk As | Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso. |
| WO2011051312A1 (en) | 2009-10-30 | 2011-05-05 | Novo Nordisk A/S | Derivatives of cgrp |
| US20130058999A1 (en) * | 2010-01-12 | 2013-03-07 | Novo Nordisk A/S | Pharmaceutical compositions for oral administration of insulin peptides |
| JP5826772B2 (ja) | 2010-02-16 | 2015-12-02 | ノヴォ ノルディスク アー／エス | コンジュゲートタンパク質 |
| WO2011101261A2 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Purification method |
| WO2011141407A1 (en) | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| US8748570B2 (en) | 2010-05-25 | 2014-06-10 | Syngene Limited | Insulin analogues |
| CN102933599A (zh) | 2010-06-23 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 包含额外的二硫键的人胰岛素 |
| WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| JP5973427B2 (ja) | 2010-06-23 | 2016-08-23 | ノヴォ ノルディスク アー／エス | 追加のジスルフィド結合を含有するインスリン類似体 |
| EP2627670A2 (en) | 2010-10-15 | 2013-08-21 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| HRP20191793T1 (hr) | 2010-10-27 | 2019-12-27 | Novo Nordisk A/S | Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja |
| EP2632478B1 (en) | 2010-10-27 | 2019-07-24 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections administered with varying injection intervals |
| CN103249427A (zh) | 2010-12-14 | 2013-08-14 | 诺沃—诺迪斯克有限公司 | 速效胰岛素联合长效胰岛素 |
| CN103370075A (zh) | 2011-02-15 | 2013-10-23 | 诺沃—诺迪斯克有限公司 | 长效il-1受体拮抗剂 |
| US20140031278A1 (en) * | 2011-03-28 | 2014-01-30 | Novo Nordisk A/S | Novel Glucagon Analogues |
| CN103458873B (zh) | 2011-04-14 | 2016-04-13 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
| US9260503B2 (en) | 2011-06-15 | 2016-02-16 | Novo Nordisk A/S | Multi-substituted insulins |
| AR088161A1 (es) * | 2011-09-23 | 2014-05-14 | Novo Nordisk As | Analogos de glucagon |
| IN2014MN00933A (enExample) * | 2011-12-15 | 2015-05-01 | Shanghai Hengrui Pharm Co Ltd | |
| JP2015502971A (ja) | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー／エス | Ｎ末端修飾インスリン誘導体 |
| EP2836508B1 (en) | 2012-04-11 | 2016-06-29 | Novo Nordisk A/S | Insulin formulations |
| US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
| AU2013255880B2 (en) | 2012-05-01 | 2017-07-20 | Novo Nordisk A/S | Pharmaceutical composition |
| EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP2908846A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk A/S | Fatty acid acylated d-amino acids for oral peptide delivery |
| LT2934567T (lt) | 2012-12-21 | 2018-09-10 | Sanofi | Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai |
| US20160296602A1 (en) * | 2013-03-20 | 2016-10-13 | Novo Nordisk A/S | Dosing Regimen |
| MX362275B (es) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| JP6499184B2 (ja) | 2013-10-07 | 2019-04-10 | ノヴォ ノルディスク アー／エス | インスリン類似体の新規な誘導体 |
| FR3013049B1 (fr) | 2013-11-14 | 2015-11-13 | You-Ping Chan | Analogue de l'insuline glargine |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9963496B2 (en) | 2014-02-18 | 2018-05-08 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| JP2018531899A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー／エス | 新規インスリン誘導体及びその医学的使用 |
| CN108026156A (zh) | 2015-08-25 | 2018-05-11 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
| EP3495384A4 (en) * | 2016-08-02 | 2020-02-26 | Jiangsu Hengrui Medicine Co., Ltd. | ACYLATED DERIVATIVE OF HUMAN INSULIN OR THE LIKE |
| WO2018096162A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| JP2019535791A (ja) | 2016-11-28 | 2019-12-12 | ノヴォ ノルディスク アー／エス | 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク |
| EP3821905B1 (en) | 2016-12-16 | 2022-10-12 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
| JOP20190273A1 (ar) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| AU2019218315A1 (en) | 2018-02-09 | 2020-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | Codon optimized precursor gene and signal peptide gene of human insulin analogue |
| AU2019272401A1 (en) | 2018-05-24 | 2021-01-14 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing precursor of recombinant human insulin or analogue thereof |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| JP7410891B2 (ja) | 2018-06-26 | 2024-01-10 | ノボ・ノルデイスク・エー／エス | 基礎インスリン滴定のための投与推奨を提供するシステム |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
| WO2021009027A1 (en) | 2019-07-12 | 2021-01-21 | Novo Nordisk A/S | High concentration insulin formulation |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| WO2021136293A1 (zh) | 2019-12-30 | 2021-07-08 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| AU2021273262A1 (en) | 2020-05-15 | 2022-12-08 | Eli Lilly And Company | Extended time action acylated insulin compounds |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4471053A1 (en) | 2022-01-28 | 2024-12-04 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| US20250154220A1 (en) * | 2023-11-15 | 2025-05-15 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (de) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
| GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DE3827533A1 (de) | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| JPH04502465A (ja) | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | ヒトインシュリン類似物質 |
| PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| EP0506792B1 (en) | 1989-12-21 | 1995-05-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| DK45590D0 (enExample) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| JP3193398B2 (ja) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | ショ−ケ−ス |
| DK0618807T3 (da) | 1991-12-20 | 2003-03-03 | Novo Nordisk As | Stabiliseret farmaceutisk formulering omfattende human væksthormon og histidin |
| BR9407508A (pt) | 1993-09-17 | 1997-01-07 | Novo Nordisk As | Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| AU3562195A (en) | 1994-10-04 | 1996-04-26 | Novo Nordisk A/S | Preparations containing aspb28 human insulin and nicotinamide |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5830999A (en) | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| AU720966B2 (en) | 1995-03-17 | 2000-06-22 | Novo Nordisk A/S | Insulin derivatives |
| DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| PT938502E (pt) | 1996-07-11 | 2005-02-28 | Novo Nordisk As | Metodo selectivo por acilacao |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| ATE264871T1 (de) | 1996-07-26 | 2004-05-15 | Aventis Pharma Gmbh | Insulinderivate mit erhöhter zinkbindung |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| AU6611998A (en) | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| ATE321783T1 (de) * | 1997-03-20 | 2006-04-15 | Novo Nordisk As | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. |
| AU6611898A (en) | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer |
| US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| SI0884053T1 (en) | 1997-06-13 | 2003-02-28 | Eli Lilly And Company | Stable insulin formulations |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| AU757933B2 (en) * | 1997-10-24 | 2003-03-13 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| EA200000453A1 (ru) | 1997-10-24 | 2000-10-30 | Эли Лилли Энд Компани | Композиции нерастворимого инсулина |
| US20020155994A1 (en) | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| WO1999034821A1 (en) | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| ES2228728T3 (es) | 1998-10-16 | 2005-04-16 | Novo Nordisk A/S | Preparaciones concentradas estables de insulina para administracion pulmonar. |
| DE60035260T2 (de) | 1999-02-22 | 2007-10-18 | The University Of Connecticut, Farmington | Neue albuminfreie faktor viii formulierungen |
| JP2002543092A (ja) | 1999-04-27 | 2002-12-17 | イーライ・リリー・アンド・カンパニー | 肺投与用インスリン結晶 |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| PT1412384E (pt) | 2001-06-28 | 2008-03-28 | Novo Nordisk As | Formulação estável de glp-1 modificado |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| WO2003075950A1 (en) | 2002-03-13 | 2003-09-18 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| DE60335797D1 (de) | 2002-05-07 | 2011-03-03 | Novo Nordisk As | Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten |
| US20050232899A1 (en) | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| US20040002451A1 (en) | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| KR100615389B1 (ko) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| NZ562480A (en) | 2002-10-29 | 2009-08-28 | Alza Corp | Stabilized, solid-state polypeptide particles |
| US20040138099A1 (en) | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| JPWO2004069259A1 (ja) | 2003-02-07 | 2006-05-25 | 味の素株式会社 | 糖尿病治療剤 |
| ES2349128T3 (es) | 2003-02-19 | 2010-12-28 | Novartis Ag | Antigeno de glucoproteina sima 135 expresado en celulas de tumor humanas metastasicas. |
| DE602004029630D1 (de) | 2003-03-04 | 2010-12-02 | Technology Dev Co Ltd | Injizierbare Insulinzubereitung mit Langzeitwirkung und Verfahren zur dessen Herstellung und Verwendung |
| ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
| US20050054818A1 (en) | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
| ES2402592T3 (es) | 2003-08-05 | 2013-05-07 | Novo Nordisk A/S | Nuevos derivados de insulina |
| CA2531988C (en) | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| KR101293503B1 (ko) | 2003-08-14 | 2013-08-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| EP1663295A2 (en) | 2003-09-01 | 2006-06-07 | Novo Nordisk A/S | Stable formulations of peptides |
| ES2229931B1 (es) | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| JP2007532096A (ja) | 2003-11-14 | 2007-11-15 | ノボ ノルディスク アクティーゼルスカブ | アシル化されたインスリンの製造方法 |
| BRPI0418115A (pt) | 2003-12-23 | 2007-04-17 | Pharmacia Corp | formulação lìquida estável de hormÈnio de crescimento |
| DE602005014962D1 (de) | 2004-03-12 | 2009-07-30 | Biodel Inc | Insulinzusammensetzungen mit verbesserter wirkstoffabsorption |
| EP1750750B1 (en) | 2004-06-01 | 2012-02-01 | Ares Trading S.A. | Method of stabilizing proteins |
| MX2007001663A (es) | 2004-08-12 | 2007-04-10 | Schering Corp | Formulacion de interferon pegilado estable. |
| AU2005277357B2 (en) | 2004-08-17 | 2011-08-04 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| JP5248113B2 (ja) | 2004-11-12 | 2013-07-31 | ノヴォ ノルディスク アー／エス | ペプチドの安定な処方 |
| ES2391776T3 (es) | 2004-11-22 | 2012-11-29 | Novo Nordisk A/S | Formulaciones solubles, estables conteniendo insulina con una sal de protamina |
| CN101106979A (zh) | 2005-01-21 | 2008-01-16 | 阿尔扎公司 | 具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂 |
| ES2438145T3 (es) * | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | Nuevos derivados de insulina |
| JP4808785B2 (ja) | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー／エス | インスリン組成物および組成物の製造方法 |
| JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | 新規インシュリン誘導体 |
| WO2007121256A2 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| AU2007247109B2 (en) | 2006-05-09 | 2012-03-15 | Novo Nordisk A/S | Insulin derivative |
| ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| ES2430042T3 (es) | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2004
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko not_active Expired - Lifetime
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en not_active Ceased
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja not_active Expired - Lifetime
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-07-04 CY CY2013027C patent/CY2013027PI2/el unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/fr active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI2/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown
-
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/el unknown
-
2024
- 2024-01-16 NO NO2024004C patent/NO2024004I1/no unknown
- 2024-01-16 NO NO2024003C patent/NO2024003I1/no unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92213I2 (fr) | Insuline dégludec sous toutes les formes protégéespar le brevet de base | |
| LU92307I2 (fr) | Elviégravir sous toutes ses formes comme protégéespar le brevet de base | |
| LU92327I2 (fr) | Ponatinib sous toutes ses formes telles que protégées par le brevet de base | |
| DK1699821T3 (da) | Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER | |
| ATE395350T1 (de) | Mit betainen stabilisierten aluminium-zirconium- glycin-antitranspirantien | |
| EP1626981A4 (en) | PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE | |
| DE602004032093D1 (de) | Polierzusammensetzung | |
| GB0301662D0 (en) | Improvements in or relating to organic compounds | |
| DE602004025205D1 (de) | Glp-1-analoga | |
| GB0323685D0 (en) | Improvements in or relating to organic compounds | |
| DE602004025173D1 (de) | Hochauflösende Leichtgewichtlupe | |
| DK1471124T3 (da) | Politursammensætning | |
| GB0316190D0 (en) | Improvements in or relating to organic compounds | |
| EP1484395A4 (en) | OPERATIONAL TRANSPOSONE IN MAMMALS | |
| ATE450173T1 (de) | Tischdecke | |
| DE602004001543D1 (de) | Tintenzusammensetzung | |
| DE502004004670D1 (de) | Rückwirkungsanordnung | |
| GB0318109D0 (en) | Improvements in or relating to organic compounds | |
| FR2851326B3 (fr) | Hotte d'extraction | |
| GB0324529D0 (en) | Improvements in or relating to organic compounds | |
| GB0301094D0 (en) | Improvements in or relating to organic compounds | |
| DE502004005995D1 (de) | Auflagefläche auflageelement | |
| GB0316040D0 (en) | Improvements in or relating to organic compounds | |
| ITRM20030246A1 (it) | Peptidi dendritici multimerici come agenti biologici | |
| ES1055367Y (es) | Fregona perfeccionada |